Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment

Swiss Medical Weekly

Volumn 144, Issue , 2014, Pages

  Reinemann, Christine ^a   Strehlitz, Beate ^a  

^a HELMHOLTZ CENTRE FOR ENVIRONMENTAL RESEARCH UFZ   (Germany)

Author keywords

Aptamers; Cancer diagnostics; Cancer therapy; DNA; Drug delivery; Imaging; Nanoparticles; RNA

Indexed keywords

APTAMER; CISPLATIN; DNA; DOCETAXEL; GOLD NANOPARTICLE; LOCKED NUCLEIC ACID; NANOPARTICLE; POLYGLACTIN; QUANTUM DOT; RNA; DIAGNOSTIC AGENT; NANOCONJUGATE;

CANCER CELL; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER THERAPY; DRUG DELIVERY SYSTEM; HYDROGEN BOND; NANOTECHNOLOGY; RADIODIAGNOSIS; REVIEW; STATIC ELECTRICITY; COMBINATORIAL CHEMISTRY; HUMAN; NEOPLASM;

APTAMERS, NUCLEOTIDE; HUMANS; NANOCONJUGATES; NEOPLASMS; SELEX APTAMER TECHNIQUE;

EID: 84899760519     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2014.13908     Document Type: Review

References (64)

1. Andy Ellington's Blog [Internet]. Austin: Andrew Ellington. 2010 July - . On Aptamers; 2011 March 6 [cited 2012 Dec 20]; [about three screens]. Available from: http://ellingtonlab.org/blog/2011/03/06/onaptamers/
2. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346(6287):818-22.
3. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505-10.
4. Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science. 2000;287(5454):820-5. (Pubitemid 30084318)
5. Ozalp VC, Eyidogan F, Oktem HA. Aptamer-gated nanoparticles for smart drug delivery. Pharmaceuticals. 2011;4(2011):1137-57.
6. Jenison RD, Gill SC, Pardi A, Polisky B. High-resolution molecular discrimination by RNA. Science. 1994;263(5152):1425-9. (Pubitemid 24137828)
7. Stoltenburg R, Reinemann C, Strehlitz B. SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng. 2007;24(4):381-403. (Pubitemid 47391579)
8. James W. Aptamers. In: Meyers RA, editor. Encyclopedia of Analytical Chemistry. Chichester: John Wiley & Sons, Ltd.; 2000. P. 4848-71.
9. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A. 2003;100(26):15416-21. (Pubitemid 38021004)
10. Sefah K, Shangguan D, Xiong XL, O'Donoghue MB, Tan WH. Development of DNA aptamers using Cell-SELEX. Nature Protoc. 2010;5(6):1169-85.
11. Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B. 1999;732(1):203-12. (Pubitemid 29421761)
12. Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons. Curr Med Chem. 2011;18(27):4206-14.
13. Carlson B. Aptamers: The New Frontier In Drug Development? Biotechnol Healthc. 2007;(April):31-5.
14. Vallian S, Khazaei MR. Medical applications of aptamers. Res Pharm Sci. 2007;2(2):59-66.
15. Lee JF, Stovall GM, Ellington AD. Aptamer therapeutics advance. Curr Opin Chem Biol. 2006;10(3):282-9. (Pubitemid 43815776)
16. Green LS, Jellinek D, Bell C, Beebe LA, Feistner BD, Gill SC, et al. Nuclease-Resistant Nucleic-Acid Ligands to Vascular-Permeability Factor Vascular Endothelial Growth-Factor. Chem Biol. 1995;2(10):683-95.
17. Rhodes A, Deakin A, Spaull J, Coomber B, Aitken A, Life P, et al. The generation and characterization of antagonist RNA aptamers to human oncostatin M. J Biol Chem. 2000;275(37):28555-61.
18. Dougan H, Lyster DM, Vo CV, Stafford A, Weitz JI, Hobbs JB. Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl Med Biol. 2000;27(3):289-97. (Pubitemid 30314723)
19. Klussmann S. The Aptamer Handbook. Functional Oligonucleotides and Their Applications. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA; 2006.
20. Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol. 2003;21(2):74-81. (Pubitemid 36165007)
21. Schmidt KS, Borkowski S, Kurreck J, Stephens AW, Bald R, Hecht M, et al. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res. 2004;32(19):5757-65. (Pubitemid 39619159)
22. Burke DH, Scates L, Andrews K, Gold L. Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. J Mol Biol. 1996;264(4):650-66. (Pubitemid 27013551)
23. Wilson C, Nix J, Szostak J. Functional requirements for specific ligand recognition by a biotin-binding RNA pseudoknot. Biochemistry. 1998;37(41):14410-9. (Pubitemid 28489047)
24. Xiao Z, Farokhzad OC. Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS Nano. 2012;6(5):3670-6.
25. Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W. Applications of aptamers in cancer cell biology. Anal Chim Acta. 2008;621(2):101-8.
26. Fang X, Tan W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res. 2010;43(1):48-57.
27. Shangguan DH, Cao ZHC, Li Y, Tan WH. Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem. 2007;53(6):1153-5. (Pubitemid 46867534)
28. Shangguan D, Li Y, Tang ZW, Cao ZHC, Chen HW, Mallikaratchy P, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A. 2006;103(32):11838-43. (Pubitemid 44215773)
29. Mallikaratchy P, Tang ZW, Kwame S, Meng L, Shangguan DH, Tan WH. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol Cell Proteomics. 2007;6(12):2230-8.
30. Tang ZW, Shangguan D, Wang KM, Shi H, Sefah K, Mallikratchy P, et al. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem. 2007;79(13):4900-7. (Pubitemid 47051443)
31. Zhang K, Tan T, Fu JJ, Zheng T, Zhu JJ. A novel aptamer-based competition strategy for ultrasensitive electrochemical detection of leukemia cells. Analyst. 2013;138(21):6323-30.
32. Sheng W, Chen T, Tan W, Fan ZH. Multivalent DNA Nanospheres for Enhanced Capture of Cancer Cells in Microfluidic Devices. ACS Nano. 2013;7(8):7067-76.
33. Medley CD, Smith JE, Tang Z, Wu Y, Bamrungsap S, Tan W. Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. Anal Chem. 2008;80(4):1067-72. (Pubitemid 351272339)
34. Liu G, Mao X, Phillips JA, Xu H, TanW, Zeng L. Aptamer-nanoparticle strip biosensor for sensitive detection of cancer cells. Anal Chem. 2009;81(24):10013-8.
35. Chen X, Estevez MC, Zhu Z, Huang YF, Chen Y, Wang L, et al. Using aptamer-conjugated fluorescence resonance energy transfer nanoparticles for multiplexed cancer cell monitoring. Anal Chem. 2009;81(16):7009-14.
36. Herr JK, Smith JE, Medley CD, Shangguan D, Tan W. Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. Anal Chem. 2006;78(9):2918-24. (Pubitemid 43726108)
37. Lu W, Arumugam SR, Senapati D, Singh AK, Arbneshi T, Khan SA, et al. Multifunctional oval-shaped gold-nanoparticle-based selective detection of breast cancer cells using simple colorimetric and highly sensitive two-photon scattering assay. ACS Nano. 2010;4(3):1739-49.
38. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002;62(14):4029-33. (Pubitemid 34791070)
39. Walter JG, Petersen S, Stahl F, Scheper T, Barcikowski S. Laser ablation-based one-step generation and bio-functionalization of gold nanoparticles conjugated with aptamers. J Nanobiotechnology. 2010;8:21.
40. Ferreira CS, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol. 2006;27(6):289-301. (Pubitemid 44646223)
41. Cheng AK, Su H, Wang YA, Yu HZ. Aptamer-based detection of epithelial tumor marker mucin 1 with quantum dot-based fluorescence readout. Anal Chem. 2009;81(15):6130-9.
42. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther. 2006;5(12):2957-62. (Pubitemid 46092036)
43. Watanabe T, Hirano K, Takahashi A, Yamaguchi K, Beppu M, Fujiki H, et al. Nucleolin on the cell surface as a new molecular target for gastric cancer treatment. Biol Pharm Bull. 2010;33(5):796-803.
44. Ko MH, Kim S, Kang WJ, Lee JH, Kang H, Moon SH, et al. In vitro derby imaging of cancer biomarkers using quantum dots. Small. 2009;5(10):1207-12.
45. Hua X, Zhou Z, Yuan L, Liu S. Selective collection and detection of MCF-7 breast cancer cells using aptamer-functionalized magnetic beads and quantum dots based nano-bio-probes. Anal Chim Acta. 2013;788:135-40.
46. Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol. 1997;4(11):809-16. (Pubitemid 28000621)
47. Javier DJ, Nitin N, Levy M, Ellington A, Richards-Kortum R. Aptamertargeted gold nanoparticles as molecular-specific contrast agents for reflectance imaging. Bioconjug Chem. 2008;19(6):1309-12. (Pubitemid 351874954)
48. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 2010;4(7):3689-96.
49. Zhou J, Soontornworajit B, Martin J, Sullenger BA, Gilboa E, Wang Y. A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling. Macromol Biosci. 2009;9(9):831-5.
50. Hwang do W, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med. 2010;51(1):98-105.
51. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1-16.
52. Chen T, Shukoor MI, Chen Y, Yuan Q, Zhu Z, Zhao Z, et al. Aptamer-conjugated nanomaterials for bioanalysis and biotechnology applications. Nanoscale. 2011;3(2):546-56.
53. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64(21):7668-72. (Pubitemid 39446893)
54. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315-20.
55. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869-76. (Pubitemid 44667020)
56. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008;105(7):2586-91. (Pubitemid 351520557)
57. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105(45):17356-61.
58. Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A. 2010;107(42):17939-44.
59. Wang AZ, Bagalkot V, Vasilliou CC, Gu F, Alexis F, Zhang L, et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem. 2008;3(9):1311-5.
60. Aravind A, Jeyamohan P, Nair R, Veeranarayanan S, Nagaoka Y, Yoshida Y, et al. AS1411 aptamer tagged PLGA-lecithin-PEG nano-particles for tumor cell targeting and drug delivery. Biotechnol Bioeng. 2012;109(11):2920-31.
61. Lopez-Colon D, Jimenez E, You M, Gulbakan B, Tan W. Aptamers: turning the spotlight on cells. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(3):328-40.
62. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307(5709):538-44. (Pubitemid 40165671)
63. Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release. 2011;153(1):16-22.
64. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008;60(11):1241-51.